Nonpharmacoloqical and pharmacological interventions for symptoms in Alzheimer's disease

Expert Review of Neurotherapeutics

Volumn 4, Issue 5, 2004, Pages 809-821

  Overshott, Ross ^a   Byrne, Jane ^a   Burns, Alistair ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Aggression; Agitation; Alzheimer's disease; Apathy; Behavioral disturbance; Depression; Nonpharmacological; Pharmacological; Sleep disturbance

Indexed keywords

ALPRAZOLAM; AMANTADINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLOMIPRAMINE; DONEPEZIL; GABAPENTIN; GALANTAMINE; HALOPERIDOL; IMIPRAMINE; MOCLOBEMIDE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; OXYCODONE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; UNINDEXED DRUG; VALPROATE SEMISODIUM; ZIPRASIDONE;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; APATHY; BEHAVIOR THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DRUG CHOICE; DRUG EFFICACY; HUMAN; PHOTOTHERAPY; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSORY STIMULATION; SLEEP DISORDER; SYSTEMATIC REVIEW; TREATMENT INDICATION; BEHAVIOR; CAREGIVER; DRUG THERAPY; EXPERT WITNESS; MENTAL DISEASE; METHODOLOGY; TREATMENT OUTCOME;

ALZHEIMER DISEASE; BEHAVIOR THERAPY; BEHAVIORAL SYMPTOMS; CAREGIVERS; DRUG THERAPY; EXPERT TESTIMONY; HUMANS; MENTAL DISORDERS; PHOTOTHERAPY; TREATMENT OUTCOME;

EID: 4444284168     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.5.809     Document Type: Review

References (117)

1. Finkel SI, Costa E, Silva J, Cohen G, Miller S, Sartorius N. Behavioural and psychological signs and symptoms in dementia: a consensus statement on current knowledge and implications for research and treatment. Int. Psychogeriatr. 8(Suppl. 3), 497-500 (1996).
2. Margallo-Lana M, Swann A, O'Brien J et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int. J. Geriatr. Psychiatry 16(1), 39-44 (2001).
3. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44(12), 2308-2314 (1994).
4. Steinberg M, Sheppard J-M, Tschanz JT et al. The incidence of mental and behavioral disturbances in dementia: The Cache County study. J. Neuropsychiatry Clin. Neurosci. 15(3), 340-345 (2003).
5. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease: disorders of thought content. Br. J. Psychiatry. 157, 92-94 (1990).
6. Tariot PN. Treatment of agitation in dementia. J. Clin. Psychiatry 60(Suppl. 8), 11-20 (1999).
7. Cohen-Mansfield J, Werner P, Freedman L. Sleep and agitation in agitated nursing home residents: an observational study. Sleep 18(8), 674-680 (1995).
8. Aalten P, de Vugt ME, Lousberg R et al. Behavioural problems in dementia: a factor analysis of the Neuropsychiatry Inventory. Dement. Geriatr. Cogn. Disord. 15(2), 99-105 (2003).
9. Cohen-Mansfield J. Nonpharmacologic interventions for psychotic symptoms in dementia. J. Geriatr. Psychiatry Neurol. 16, 219-224 (2003).
10. Mintzer J, Targum SD. Psychosis in elderly patients: classification and pharmacotherapy. J. Geriatr. Psychiatry Neurol. 16, 199-206 (2003).
11. Hart DJ, Craig D, Compton SA et al. A retrospective study of the behavioural and psychological symptoms of mid and late phase Alzheimer's disease. Int. J. Geriatr. Psychiatry 18(11), 1037-1042 (2003).
12. Coen Rf, Swanwick GR, O'Boyle CA, Coakley D. Behaviour disturbance and other predictors or carer burden in Alzheimer's disease. Int. J. Geriatr. Psychaitry 12(3), 331-336 (1997).
13. O'Donnell BF, Drachman OA, Barnes HJ, Peterson KE, Swearer JM, Lew RA. Incontinence and troublesome behaviors predict institutionalization in dementia. J. Geriatr. Psychiatry Neurol. 5(1), 45-52 (1992).
14. Paulsen JS, Salmon DP, Thai LJ et al. Incidence of and risk factors for hallucinations and delusions in patients with probable Alzheimer's disease. Neurology 54(10), 1965-1971 (2000).
15. Wimo A, Ljunggren G, Winbland B. Costs of dementia and dementia care: a review. Int. J. Geriatr. Psychiatry. 12(8), 841-846 (1997).
16. Bosanquet N, May J, Johnson N. Alzheimer's disease in the UK: burden of disease and further care. Health Policy Review Paper 12. Imperial School of Medicine, London, UK (1998).
17. McShane R, Keene J, Gedling K, Fairburn C, Jacoby R, Hope T. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow-up. Br. Med. J. 314, 266-270 (1997).
18. Cohen-Mansfield J, Billig N. Agitated behaviours in the elderly. J. Am. Geriatr. Soc. 34(10), 711-721 (1986).
19. Patel V, Hope T. Aggressive behaviour in elderly people with dementia: a review. Int. J. Geriatr. Psychiatry 8(3), 457-472 (1993).
20. Mungas D, Weiler V, Franzi C, Henry R. Assessment of disruptive behaviour associated with dementia: the disruptive behaviour rating scale. J. Geriatr. Psychiatry Neurol. 2(4), 196-202 (1989).
21. Potts HW, Richie MF, Kaas MJ. Resistance to care. J. Gerontol. Nurs. 22(11), 11-16 (1996).
22. Gormley N, Lyons D, Howard R. Behavioural management of aggression in dementia: a randomised controlled trial. Age Ageing 30(2), 141-145 (2001).
23. Lai CKY, Arthur DG. Wandering behaviour in people with dementia. J. Adv. Nurs. 44(2), 173-182 (2003).
24. Teri L, Logsdon RG, Peskind E et al. Treatment of agitation in AD. A randomized, placebo-controlled clinical trial. Neurology 55, 1271-1278 (2000). One of the few studies that compares a nonpharmacological with pharmacological interventions and placebo. Methodological difficulties may led to positive findings not beiag shown.
25. Alessi CA, Yoon Ej, Schnelle JF, Nhahla R, Al-Samarrai MS, Cruise PA. A randomised trial of a combined physical activity and environmental intervention in nursing home residents: do sleep and agitation improve? J. Am. Geriatr. Soc. 47(7), 784-791 (1999).
26. Rovner B, Steele CD, Shmuely Y, Folstein MF. A randomised trial of dementia care in nursing homes. J. Am. Geriatr. Soc. 44(1), 7-13 (1996).
27. Kim EJ, Buschmann MT. The effect of expressive physical touch on patients with dementia. Int. J. Nurs. Stud. 36(3), 235-243 (1999).
28. Synder M, Egan EC, Burns KR. Efficacy at hand massage in decreasing agitation behaviours associated with care activities in person with dementia. Geriatr. Nurs. 16(2), 60-63 (1995).
29. Neal M, Briggs M. Validation therapy for dementia (Cochrane Review). In: Cochrane Library Issue 1. John Wiley and Sons Ltd, Chichester, UK (2004).
30. Spector A, Orrell M, Davies S et al. Reminiscence therapy for dementia (Cochrane Review). In: Cochrane Library Issue 3, Update software, Oxford, UK (2002).
31. Spector A, Orrell M, Davies S, Woods RT. Reality orientation for dementia (Cochrane Review). In: Cochrane Library Issue 2. Update software, Oxford, UK (2002).
32. Koger SM, Chapin K, Brotons M. Is music therapy an effective intervention for dementia: a meta-anarytic review of literature. J. Music Ther. 36(1), 2-15 (1999).
33. Gerdner LA. Effects of individualised versus classical relaxation music on the frequency of agitation in elderly persons with Alzheimer's disease and related disorders. Int. Psychogeriatr. 12(1), 49-65 (2000).
34. Cohen-Mansfield J, Werner P. Management of verbally disruptive behaviours in nursing home residents. J. Gerontol. 52(6), M369-M377 (1997).
35. Ballard CG, O'Brien JT, Reichelt K, Perry EK. Aromatherapy as safe and effective treatment for the management agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. J. Clin. Psychiatry 63(7), 553-558 (2002). Good example of a well conducted randomized clinical trial (RTC) studying a nonpharmacological intervention.
36. Smallwood J, Brown R, Coulter F, Irvine E, Copland C. Aromatherapy and behaviour disturbances in dementia: a randomised controlled trial. Int. J. Geriatr. Psychaitry 16(10), 1010-1013 (2001).
37. Holmes C, Hopkins V, Hensford C, MacLaughlin V, Wilkinson D, Rosenvinge H. Lavender oil as a treatment for agitated behaviour in severe dementia: placebo-controlled study. Int. J. Geriatr. Psychiatry 17(4), 305-308 (2002).
38. Haffmans PMJ, Sival RC Lucius SA, Cats Q, van Gelder L. Bright light therapy and melatonin in motor restlessness behaviour in dementia: a placebo-controlled study. Int. J. Geriatr. Psychiatry 16(1), 106-110 (2001).
39. Satlin A, Volicer L, Ross V, Herz L, Campbell S. Bright light treatment of behavioural and sleep disturbances in patients with Alzheimer's disease. Am. J. Psychiatry 149(8), 1028-1032 (1992).
40. Lyketsos CG, Lindell Veiel L, Baker A, Steele C. A randomized, controlled trial of bright light therapy for agitated behaviours in dementia patients residing in long-term care. Int. J. Geriatr. Psychiatry 14(7), 520-525 (1999).
41. Chung JCC, Lai CKY, Chung PMB, French HP. Snoezelen for dementia (Cochrane Review). In: The Cochrane Library Issue 1. John Wiley and Sons Ltd, Chichester, UK
42. Green A, Brodaty H. Caregiver interventions. In: Evidence-Based Dementia Practice. Qizilbash N, Schneider H, Chui H et al. (Eds). Blackwell Publishing, Oxford, UK, 764-794 (2002).
43. McCallion P, Toseland RW, Lacey D, Banks S. Educating nursing assistants to communicate more effectively with nursing home residents with dementia. Gerontologist 39(5), 546-558 (1999).
44. Haupt M, Karger A, Janner M. Improvement of agitation and anxiety in demented patients after psychoeducational group intervention with their caregivers. Int. J. Geriatr. Psychiatry 15, 1125-1129 (2000).
45. Proctor R, Burns A, Powell H et al. Behavioural management in nursing and residential homes: a randomised controlled trial. Lancet 354(9172), 26-29 (1999).
46. McGrath AM, Jackson GA. Survey of neuroleptics prescribing in residents of nursing homes in Glasgow. Br. Med. J. 312(7031), 611-612 (1996).
47. Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J. Am. Geritr. Soc. 38(5), 553-563 (1990). A meta-analysis which first highlighted the efficacy of antipsychotic medications in dementia.
48. Kindermann SS, Dolder CR, Bailey A, Katz JR, Jeste DV. Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience. Drugs Ageing 19(4), 257-276 (2002). A more up to date analysis of antipsychaotic use in dementia which demonstrates not only efficacy but also the improved side-effect profile of atypical antipsychotics.
49. DeDeyn PP, Rabheru K, Ramussen A et al. A randomised trial of risperidone, placebo, and haloperidol for behavioural symptoms of dementia. Neurology 53(5), 946-955 (1999).
50. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: a randomised double-blind trial. J. Clin. Psychiatry 60(2), 107-115 (1999).
51. Street J, Clark WS, Cannon KS et al. Olanzapine treatment of psychotic and behavioural symptoms in patients with Alzheimer's disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU study group. Arch. Gen. Psychiatry 57(10), 968-976 (2000).
52. Herrmann N, Mamdani M, Lanctôt KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am. J. Psychiatry 161, 1113-1115 (2004).
53. Tariot PN, Ismail MS. Use of quetiapine in elderly patients. J. Clin. Psychiatry 63(Suppl. 13), 21-26 (2002).
54. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am. J. Psychiatry 157(1), 4-15 (2000).
55. Winbald B, Engedal K, Soininen H. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57(3), 489-495 (2001).
56. Tariot PN, Cummings J, Katz T et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J. Am. Geriatr. Soc. 49(12), 1590-1599 (2001).
57. Feldman H, Gauthier S, Hecker J, Velles B, Subbiah P, Whalen E. for the donepezil MSAD Study Investigators Group. A 24-week, randomised, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57(4), 613-620 (2001).
58. Rosier M, Anand R, Cicin-Sian A et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. Br. Med. J. 318(7184), 633-638 (1999).
59. Corey-Bloom JF, Anand R, Veach J. A randomised trial evaluating and efficacy and safety of ENA 713 (rivastigmine tartarte) a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int. J. Geriatr. Psychopharmacol. 1(2), 55-65 (1998).
60. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilenfeld S, Ding SC for the Galantamine USA-10 Study Group. A 5-month, randomised, placebo-controlled trial of galantamine Alzheimer's disease. Neurology 54(12), 2269-2276 (2000).
61. Tariot PN, Erb R, Podgorski CA et al. Efficacy and tolerability of carbamazepine for agitation and agression in dementia. Am. J. Psychiatry 155(1), 54-61 (1998).
62. Porsteinsson AP, Tariot PN, Erb R et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am. J. Geriatr. Psychiatry 9(1), 58-66 (2001).
63. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. Br. J. Psychiatry 157, 894-901 (1990).
64. Lawlor BA, Radcliffe J, Molchan SE, Martinez RA, Hill JL, Sunderland T. A pilot placebo-controlled study of trazodone and buspirone in Alzheimer's disease. Int. J. Geriatr. Psychiatry 9(1), 55-59 (1994).
65. Enkel SI, Mintzer JE, Dysken M, Krishman KRR, Burt T, McRae T. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int. J. Geriatr. Psychiatry 19(1), 9-18 (2004).
66. Chesrow EJ, KAplitz SE, Vetra H, Breme JT, Marquardt GH. Blind study of oxazepam in the management of geriatric patients with behavioral problems. Clin. Med. 13, 1001-1005 (1965).
67. De Lemos GP, Clement WR, Nickels E. Effect of diazepam suspension in geriatric patients hospitalised for psychiatric illnesses. J. Am. Geriatr. Soc. 13, 355-359 (1965).
68. Coccaro EF, Kramer E, Zemishlany Z et al. Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. Am. J. Psychiatry 147, 1640-1645 (1990).
69. Stotsky B. Multicenter study comparing thioridazine with diazepam and placebo in elderly, nonpsychotic patients with emotional and behavioral disorders. Clin. Therapeutics 6, 546-559 (1984).
70. Christensen DB, Benfield WR. Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facilities patients. J. Am. Geriatr. Soc. 46, 620-625 (1998).
71. Manfredi PL, Breuer B, Wallenstein S, Stegmann M, Bottomley G, Libow L. Opioid treatment for agitation in patients with advanced dementia. Int. J. Geriatr. Psychiatry 18(8), 700-705 (2003).
72. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioural changes in Alzheimer's disease. Neurology 46(1), 130-135 (1996).
73. Landes AM, Sperry SD, Strauss ME, Geldmacher DS. Apathy in Alzheimer's disease. J. Am. Geriatr. Soc. 49(12), 1700-1707 (2001). Apathy is a poorly recognized symptom. This is an excellent review and discussion of the subject.
74. Robert PH, Clairet S, Benoit M et al. The Apathy Inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinsons disease and mild cognitive impairment. Int. J. Geriatr. Psychiatry 17(12), 1099-1105 (2002).
75. Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychaitry Res. 38(2), 143-162 (1991).
76. Teri L, Logsdon RG, Uomoto J, McCurry SM. Behavioural treatment of depression in dementia patients: a control trial. J. Gerontol B. Psychol. Sci. Soc. Sci. 52(4), 159-166 (1997).
77. Campbell JJ, Duffy JD. Treatment strategies in amotivated patients. Psychiatric Ann. 27, 44-49 (1997).
78. Marin RS. Apathy and related disorders of diminished motivation. In: Review of Psychiatry. Volume 15. Dickstein LJ, Riba MB, Oldaham JM (Eds). American Psychiatric Press, Washington DC, USA, 205-242 (1996).
79. McMahon S, Kermode S. A clinical trial of the eflect of aromatherapy on motivational behaviour in a dementia care setting using a single subject design. Aust. J. Holist. Nurs. 5(2), 47-49 (1996).
80. Lord TR, Garner JE. Effects of music therapy on Alzheimer patients. Percept. Mot. Skills 76(2), 451-455 (1993).
81. Gauthier S, Feldman, Hecker J et al. Efficacy of donepezil on behavioural symptoms in patients with moderate to severe Alzheimer's disease. Int. Psychogeriatr. 14(4), 389-404 (2002).
82. Dartigues JF, Goulley F, Bourdiex I, Pere JJ, Barberger-Gareau P. Rivastigmine in current clinical practice in patients with mild-to-moderate Alzheimer's disease. Rev. Neurol. 158(8-9), 807-812 (2002).
83. Cummings J, Anand R, Koumaras B, Hartman R. Rivastigrnine provides behavioural benefits to Alzheimer's disease patients in the nursing home. Findings from a 26 week trial. Neurology 54(Suppl. 3), A468 (2000).
84. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilenfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. Lancet 359(9314), 1283-1290 (2002).
85. Marin RS, Fogel BS, Hawkins J, Duffy J, Krupp B. Apathy: a treatable syndrome. J. Neuropsychiatry Clin. Neurosci. 7(1), 23-30 (1995).
86. Weiner MF, Debus JR, Goodkin K. Pharmacological management and treatment of dementia and secondary symptoms. In: The Dementias: Diagnosis and Management. Weiner MF (Ed.). American Psychiatric Press, Washington DC, USA 135-166 (1991).
87. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease III: disorders of mood. Br. J. Psychiatry 157, 81-86 (1990).
88. Rubin ER, Veiel LL, Kinscharf DA, Morris JC, Storandt M. Clinically significant depressive symptoms and very mild-to-mild dementia of the Alzheimer type. Int. J. Geriatr. Psychiatry 16(7), 694-701 (2001).
89. Purandare N, Burns A, Craig S, Faragher B, Scott K. Depressive symptoms in patients with Alzheimer's disease. Int. J. Geriatr. Psychiatry 16(10), 960-964 (2001).
90. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. Biol. Psychiatry 23(3), 271-284 (1988).
91. Lyketsos GG, Steele C, Galik E et al. Physical aggression in dementia patients and its relationship to depression. Am. J. Psychaitry 156(1), 66-71 (1999).
92. Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of literature. J. Am. Geriatr. Soc. 51(9), 1305-1317 (2003). Good review of assessment and treatment of behavioral disturbance of nursing home residents with dementia which includes open-label studies as well as RCTs.
93. Cheston R, Jones K, Giliiard J. Group psychotherapy and people with dementia. Aging Ment. Health 7(6) 452-461 (2003).
94. Goldwasser AN, Auerbach SM, Harkins SW. Cognitive, affective and behavioural effects of reminiscence group therapy on demented elderly. Int. J. Aging Hum. Av. 25(3), 209-222 (1987).
95. Ashida S. The effect of reminiscence music therapy sessions on changes in depressive symptoms in elderly persons with dementia. J. Musc. Ther. 37(3), 170-182 (2000).
96. Sumaya IC, Rienzi BM, Deegen JF II, Moss DE. Bright light treatment decreases depression in institutionalized older adults: a placebo-controlled crossover study. J. Gerontol. A. Biol. Sci. Med. Sci. 56(6), M356-M360 (2001).
97. Brodaty H, Green A, Koschera A. Meta-analysis of psychosocial intervention for caregivers of people with dementia. J. Am. Geriatr. Soc. 51(5), 657-664 (2003).
98. Katona CL, Hunter BN, Bray J. A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int. J. Geriatr. Psychiatry 13(2), 100-108 (1998).
99. Lyketsos CG, Sheppard JM, Steele CN. Randomised, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease. Am. J. Psychiatry 157(10), 1686-1689 (2000).
100. Trappler B, Cohen CI. Use of SSRIs in very old depressed nursing home residents. Am. J. Geriatr. Psychiatry 6(1), 83-89 (1998).
101. Magai C, Kennedy G, Cohen CI, Gomberg D. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. Am. J. Geriatr. Psychiatry 8(1), 66-74 (2000).
102. Lyketsos CG, DelCampo L, Steinberg M et al. Treating depression in Alzheimer's disease. Arch. Gen. Psychiatry 60, 737-746 (2003).
103. van der Wuff FB, Stek ML, Hoogendijk WJG, Beekman AT. The efficacy and safety of ECT in depressed older adults: a literature review. Int. J. Geriatr. Psychiatry 18(10), 894-904 (2003).
104. Vitiello MV, Prinz PN. Sleep disturbances in the elderly. In: Clinical Neurology of Aging. Albert ML, Knoefel JE (Eds). Oxford University Press, NY, USA, 637-650 (1994).
105. Vitellio MV, Poceta JS, Prinz PN. Sleep in Alzheimer's disease and other dementing disorders. Can. J. Psychol. 45, 221-239 (1992).
106. Montgomery P, Dennis J. A systematic review of nonpharmacological therapies for sleep problems in later life. Sleep Metab. Rev. 8(1), 47-62 (2004).
107. Beullens J, Schols J. Treatment of insomnia in demented nursing home patients: a review. Tjdschr. Gerontol. Geriatr. 33(1), 15-20 (2002).
108. McCurry SM, Gibbons LE, Logsdon RG, Vitiello M, Teri L. Training caregivers to change the sleep hygiene practices of patients with dementia: the NITE-AD project. J. Am. Geriatr. Soc. 51(10), 1455-1460 (2003).
109. Allen H, Byrne EJ, Sutherland D, Tomenson B, Butter B, Burns A. Bright light therapy, diurnal rhythm and sleep on dementia. Int. Psychogeriatrics 15(Suppl. 12), 97-98 (2003).
110. Thorgrimsen L, Spector A, Wiles A, Orrell M. Aromatherapy for dementia (Cochrane Review). In: The Cochrane Library, Issue 1. John Wiley & Sons Ltd, Chichester, UK (2004).
111. Lindenmuth GF. Effects of music on sleep in healthy elderly and subjects with senile dementia of the Alzheimer type. Am. J. Alzheimers Care Rel. Dis. Report 3l4, 13-20 (1992).
112. Linnoila M, Viukari M, Lamminsiva A, Auvinen J. Efficacy and side effects of lorazepam, oxazepam and temazepam as sleeping aids in psychogeriatric inpatients. Int. Pharmacopsychiatry 15(2), 129-135 (1980).
113. Shaw SH, Curson H, Coquelin JP. A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric inpatients. J. Int. Med. Res. 20(2), 150-161 (1992).
114. Serfaty M, Kendell-Webb S, Warner J, Blizard R, Raven P. Double-blind randomised placebo-controlled trial of low dose melatonin for sleep disorders in dementia. Int. J. Geriat. Psychiatry 17(12), 1120-1127 (2002).
115. Singer C, Tractenberg RE, Kaye J et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 26(7), 893-901 (2003).
116. Kittur S, Hauser P. Improvement of sleep and behavior by methylphenidate in Alzheimer's disease. Am. J. Psychiatry 156(7) 1116-1167 (1999).
117. Cooper B. Thinking preventively about dementia: a review. Int. J. Geriatr. Psychiatry 17(10), 895-906 (2002).